Drugs / ALN-ANG3
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06452771 | Jun 2024 → Dec 2026 expected | hypertriglyceridemia 2 | Regeneron Pharmaceuticals | Active not recruiting | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07271186 | Jan 2026 → Sep 2027 expected | diabetic kidney disease | Regeneron Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | ALN-ANG3 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06452771 ↗ |
| Action | Inhibit | “ANGPTL3 inhibition” NCT07271186 ↗ |
| Modality | Small interfering RNA (siRNA) | “Small-Interfering RNA” NCT07271186 ↗ |
| Target | ANGPTL3 | “ANGPTL3 inhibition” NCT07271186 ↗ |